Maipl Therapeutics
Maipl Therapeutics: NY-based medical firm innovating first-in-class medicines for endometriosis and more.
Founded
2023Maipl Therapeutics: NY-based medical firm innovating first-in-class medicines for endometriosis and more.
Maipl Therapeutics, founded in Scarsdale, New York, is committed to developing innovative, first-in-class medicines targeting endometriosis and other diseases. Their core mission is to create highly selective treatments that address underlying causes of various conditions without affecting essential bodily functions. The company's flagship product, MA-7107, is a potent inhibitor of prostaglandin F2α signaling, designed to treat diseases by selectively antagonizing this pathway.
Notable figures associated with Maipl Therapeutics include leading scientists and medical professionals dedicated to advancing precision therapies. The company has garnered attention for its groundbreaking approach to treating conditions traditionally underserved by existing pharmaceuticals. By focusing on selective inhibition of prostaglandin pathways, Maipl Therapeutics aims to offer safer and more effective treatment options, potentially transforming the landscape of medical therapeutics for diseases like endometriosis.
Companies similar to Maipl Therapeutics include Maia Pharmaceuticals, MDI Therapeutics, Moerae Matrix and Plumeria Therapeutics.
Maipl Therapeutics was founded in 2023.
Maipl Therapeutics' headquarters is located in Scarsdale, NY, US.
Maipl Therapeutics' most recent funding round was for $135k (USD) in December 2023.
As of Dec 15, 2023, Maipl Therapeutics has disclosed funding of $135k (USD). Undisclosed round amounts are excluded.
Maipl Therapeutics has 7 employees as of Feb 4, 2024.
Plumeria Therapeutics
